Chris Lavictoire Mahai

Director Chris Lavictoire Mahai buys 527 shares of HQL at $19.92; first position

Chris Lavictoire Mahai, a director of abrdn Life Sciences Investors (HQL), made an initial purchase of 527 shares at $19.92 on 2026-07-16, establishing a position in the fund for the first time. The stock has risen 9.6% over the prior 30 days and 9.9% over 90 days, and is currently trading at $19.68, only 7.7% below its 52-week high of $21.32. This transaction represents a relatively modest acquisition in dollar terms ($10,497.84) and signals director participation in the fund, though the lack of prior holding history and modest share count limit the interpretive weight of this single trade.

Director Chris Lavictoire Mahai buys 501 HQH shares at $20.96; opens new position

Chris Lavictoire Mahai purchased 501 shares at $20.96, establishing an initial position in abrdn Healthcare Investors with no prior holdings. The entry price sits within the 52-week range of $15.51–$22.29, approximately -6.1% from the 52-week high. Over the 30-day and 90-day periods, the stock has posted gains of +3.7% and +6.1% respectively, suggesting positive momentum preceding this transaction. This represents a modest purchase totaling $10,500.96 and warrants observation to determine whether the director's initiation signals material conviction in the healthcare strategy or represents a routine portfolio addition.

Director Chris Lavictoire Mahai buys 796 shares of THW at $13.20; establishes initial position

Chris Lavictoire Mahai purchased 796 shares of abrdn World Healthcare Fund (THW) at $13.20 on 2026-07-16 for a total value of $10,507.20, establishing an initial position from zero prior holdings. The transaction occurred near the 52-week high of $13.79 (3.1% below peak) and follows a 30-day price appreciation of 5.3% and 90-day appreciation of 6.4%, placing the entry point in a context of recent positive momentum. As a director acquiring a fund holding for the first time, the purchase creates a measurable stake but the modest share count and absolute dollar value ($10.5K) suggest this is a limited commitment rather than a major capital deployment.

Director Chris Lavictoire Mahai bought 568 shares of THQ at $18.49; new position, currently trading at $18.87.

Director Chris Lavictoire Mahai initiated a position in abrdn Healthcare Opportunities Fund (THQ) with a purchase of 568 shares at $18.49 on 2026-07-16, valued at $10,502.32. The stock is currently trading at $18.87, slightly above the transaction price, and has risen 1.4% over the past 30 days and 3.4% over 90 days. This represents a new holding for Mahai with no prior position in THQ. The transaction is modest in absolute terms and reflects a small portfolio entry at a price near the 52-week midpoint, with limited context available to interpret the director's underlying rationale.